EQS-News: Marinomed Biotech AG reports increase in revenues for the first 9 months 2022 and significant business development progress
Despite the challenging environment, 2022 has to date been a very successful year for Marinomed.
- Despite the challenging environment, 2022 has to date been a very successful year for Marinomed.
- Revenues for the first 9 months of 2022 increased to 7.1m compared to the previous year (9M 2021 5.7m; +24%).
- Marinomed confirms its financial outlook for the 2022 fiscal year: The Company expects Carragelose revenues in the double digit million range, but an operating loss for 2022.
- Given the promising progress in its partnerships, Marinomed plans to reach operating profitability in the medium term.